天士力医药布局31款创新药，实现双线创新

Core Viewpoint - The market is increasingly focused on companies with innovative drug pipelines, with Tian Shi Li (600535) emerging as a significant player in the field of innovative drugs, having established a robust pipeline in various therapeutic areas [1][2]. Group 1: Company Overview - Tian Shi Li has reported a total of 83 projects in its pipeline, with 31 of these being innovative drugs, focusing on cardiovascular and metabolic diseases, neurological/psychiatric disorders, and digestive health [2][5]. - The company has made significant advancements in the field of Cellular and Gene Therapy (CGT) and antibody drugs, having received clinical approval for three products, including the world's first mesenchymal stem cell injection approved for IND in the U.S. [3][5]. Group 2: Research and Development - The company has a strong commitment to R&D, with a leading investment level in the industry, and is expected to launch several projects in the coming years, enhancing its growth prospects [5]. - Tian Shi Li is advancing its "disease tree" and "product tree" innovation strategies, with a focus on clinical trials for various innovative traditional Chinese medicines, including 29 projects currently in clinical trial stages [5][6]. Group 3: Market Trends - The biopharmaceutical industry in China is projected to exceed 2.5 trillion yuan by 2025, driven by strong policy support and technological breakthroughs, with CGT and gene therapy being key growth engines [2]. - The company is aligning with national strategies that prioritize the development of biomedicine as a strategic emerging industry, particularly in gene and cell therapy [2].